Radioactive Investigational Drug Committee (RIDC)


The Yale Radioactive Investigational Drug Committee (RIDC) ensures the appropriate use of all human subject research protocols involving the use of investigational radioactive drugs with an IND, amended IND or an FDA allowed IND exemption (as well as the use of FDA-approved radiopharmaceuticals.) Subject to the Yale University’s Institutional Review Board’s final approval, the RIDC has the authority to approve, disapprove or require modifications to the protocol, consent form, and other study related documents related to the use of radiopharmaceuticals in human subjects for research.   View a detailed list of committee members.